NovoCure Limited(纳斯达克代码:NVCR)今日盘中大跌8.38%,引发了市场广泛关注。
公司2024年第四季度财报显示,尽管该季度营收1.61亿美元高于市场预期的1.58亿美元,但每股净亏损为0.61美元,却大幅超出分析师共识预期的0.34美元亏损水平。
净亏损数据遭超预期,显然令投资者失望,这可能是导致NovoCure股价盘中大幅震荡下跌的主要原因。市场对公司盈利能力存疑,在此前景不佳的财报出炉后,投资者或选择先行减持股份。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.